Frazier Healthcare Partners announced on June 25 that it has completed its acquisition of Plantation, Florida-based BioMatrix Holdings, LLC. Frazier is partnering with Ted and Kathee Kramm, two experienced industry executives in the home infusion market, to lead BioMatrix.
BioMatrix Holdings (also called BioMatrix Specialty Infusion Pharmacy) is a national provider of home-based infusion services with clinical expertise in neurological diseases, immunology deficiencies and transplants, as well as blood disorders. BioMatrix serves a diversified base of patients with more than 2,500 physician-referral relationships across all 50 states.
Frazier Healthcare Partners is a provider of growth capital to healthcare companies. With more than $7.1 billion in total capital raised, Frazier has invested in more than 200 companies. Frazier has offices in Seattle and Menlo Park, California, and invests across the United States, Canada and Europe.
Cantor Fitzgerald & Co. and Goodwin Procter LLP served as Frazier’s financial advisor and legal counsel, respectively. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the ninth infusion services transaction of 2024. There were eight deals announced in the infusion services specialty during 2023, and 32 announced in the specialty during 2022.
